Watchlist

Watchlist
Aralez Pharmaceuticals Inc. (ARLZ)
Aralez Pharmaceuticals Inc. (ARLZ)
Aralez Pharmaceuticals: Change In Strategy May Bring A Silver Lining
Less than 2 months ago, Aralez Pharmaceuticals (Nasdaq: ARLZ ) announced its Q4 2017 and full year 2017 results, and gave optimistic financial guidance for 2018 of revenues of $140 million to $160 million and projected Adjusted EBITDA of between $35 million and $55 million. At the time thin…
Midday Gainers / Losers (05/08/2018)
Gainers: AMDA +105% . PRPH +36% . PI +29% . EGY +26% . UUU +22% . CRCM +18% . SEII +17% . NSU +17% . CDLX +15% . TCMD +16% . More news on: Amedica Corporation, ProPhase Labs, Inc., Impinj, Inc., Stocks on the move, , Read more …
Aralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q1 2018 Results - Earnings Call Transcript
Aralez Pharmaceuticals Inc. (ARLZ) Q1 2018 Results Earnings Conference Call May 08, 2018, 08:00 AM ET Executives Adrian Adams - CEO Nichol Ochsner - Executive Director of Investor Relations and Corporate Communications Michael Kaseta - CFO Analysts David Bautz - Zacks Equit…
Premarket Losers as of 9:05 am (5/8/2018)
ARLZ -26% on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more …
Aralez revenues up 47% in Q1
Aralez Pharmaceuticals ( ARLZ ) Q1 results : Revenues: $38.1M (+46.5%); Product revenues: $34M; Other revenues: $4.1M (-78.8%). More news on: Aralez Pharmaceuticals Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more …
Aralez Pharmaceuticals Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Aralez Pharmaceuticals Inc. in conjunction with their 2018 Q1 earnings Read more …
Aralez Pharmaceuticals to wind down U.S. operations; shares off 22% premarket
Citing the Yosprala flop and insufficient momentum from Zontivity to sustain its U.S. infrastructure, Aralez Pharmaceuticals (NASDAQ: ARLZ ) has decided to terminate its U.S. operations. The move should save $25M in annual expenses. More news on: Aralez Pharmaceuticals Inc., Healthcare sto…
Aralez Pharmaceuticals misses by $0.04, beats on revenue
Aralez Pharmaceuticals (NASDAQ: ARLZ ): Q1 EPS of -$0.29 misses by $0.04 . More news on: Aralez Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
Aralez Announces First Quarter 2018 Financial Results
-1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ")today announced financial results for the first qu…
Aralez Announces New Strategic Direction
-Focus on Canadian Operations, supported by Toprol-XL Franchise Revenues and Vimovo Royalties- -Discontinuation of U.S. Commercial Operations, with Significant Reductions in Operating Expenses- -Actively Exploring Strategic Alternatives for Business- MISSISSAUGA, Ont…
Aralez Pharmaceuticals Inc. (ARLZ)